During the past decade, Kansas City Research Institute conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 20 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 17 clinical trials were completed. i.e. 130.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kansas City Research Institute" #1 sponsor was "Gilead Sciences" with 7 trials, followed by "Intercept Pharmaceuticals" with 5 trials sponsored, "Bristol-Myers Squibb" with 3 trials sponsored, "Conatus Pharmaceuticals Inc." with 3 trials sponsored and "Galapagos NV" with 3 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kansas City Research Institute" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "PPD" with 2 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Kansas City Research Institute" are "Nonalcoholic Steatohepatitis" (5 trials), "Ulcerative Colitis" (5 trials), "Hepatitis C" (3 trials), "Cirrhosis" (2 trials) and "Crohn's Disease" (2 trials). Many other conditions were trialed in "Kansas City Research Institute" in a lesser frequency.

Most popular intervention types in "Kansas City Research Institute" are "Drug" (47 trials), "Biological" (4 trials), "Other" (2 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Filgotinib" (4 trials), "ABP-450" (2 trials), "Daclatasvir" (2 trials) and "Emricasan (5 mg)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kansas City Research Institute" are 50 trials for "All" genders.

Currently, there are NaN active trials in "Kansas City Research Institute". undefined are not yet recruiting, 5 are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 27 completed trials in Kansas City Research Institute, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Kansas City Research Institute, 4 "Phase 1" clinical trials were conducted, 21 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".

Kansas City Research Institute has several departments that took part in Clinical trials: "Kansas City Research Institute, LLC - Phase I Unit" - 2 trials